Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device

NCT06789224 is registered in ClinicalTrials.gov with Lindis Bloodcare GmbH as lead sponsor.

NCT NCT06789224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06789224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device
Lead sponsor
Lindis Bloodcare GmbH
Phase
Not applicable
Overall status
Completed
Start date
February 15, 2022
Completion date
April 14, 2024
Enrollment
136 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, colon carcinoma, endometrial carcinoma, gallbladder carcinoma, gastric carcinoma, kidney carcinoma, liver carcinoma, non-small cell lung cancer, ovarian carcinoma, pancreatic carcinoma, peritoneal carcinomatosis, prostate tumor